Literature DB >> 16540649

Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.

Juan Ren1, Yi-jin Xiao, Lisam Shanjukumar Singh, Xiaoxian Zhao, Zhenwen Zhao, Li Feng, Tyler M Rose, Glenn D Prestwich, Yan Xu.   

Abstract

Lysophosphatidic acid (LPA) is both a potential marker and a therapeutic target for ovarian cancer. It is critical to identify the sources of elevated LPA levels in ascites and blood of patients with ovarian cancer. We show here that human peritoneal mesothelial cells constitutively produce LPA, which accounts for a significant portion of the chemotactic activity of the conditioned medium from peritoneal mesothelial cells to ovarian cancer cells. Both production of LPA by peritoneal mesothelial cells and the chemotactic activity in the conditioned medium can be blocked by HELSS [an inhibitor of the calcium-independent phospholipase A(2) (iPLA(2))] and AACOCF(3) [an inhibitor of both cytosolic PLA(2) (cPLA(2)) and iPLA(2)]. Moreover, cell-based enzymatic activity assays for PLA(2) indicate that peritoneal mesothelial cells have strong constitutive PLA(2) activity. Receptors for LPA, LPA(2), and LPA(3) are involved in the conditioned medium-induced chemotactic activity. Invasion of ovarian cancer cells into peritoneal mesothelial cells has also been analyzed and shown to require PLA(2), LPA receptors, and the mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase signaling pathway. Thus, we show here, for the first time, that human peritoneal mesothelial cells constitutively produce bioactive lipid signaling molecules, such as LPA, via iPLA(2) and/or cPLA(2) activities. Conditioned medium from peritoneal mesothelial cells stimulate migration, adhesion, and invasion of ovarian cancer cells, and may play similar roles in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540649     DOI: 10.1158/0008-5472.CAN-05-1292

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Gang Wei; Libo Yan; Dongmei Wang; Hong Zhang; George Earl Sandusky; John Turk; Yan Xu
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

2.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

Review 3.  Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics.

Authors:  Alexander Yang; Emilio P Mottillo
Journal:  Biochem J       Date:  2020-03-13       Impact factor: 3.857

4.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

5.  Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.

Authors:  Martine Bot; Ilze Bot; Rubén Lopez-Vales; Chris H A van de Lest; Jean Sébastien Saulnier-Blache; J Bernd Helms; Samuel David; Theo J C van Berkel; Erik A L Biessen
Journal:  Am J Pathol       Date:  2010-04-29       Impact factor: 4.307

6.  Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Caryl Antalis; Zhanzhong Zhao; Robert Emerson; Gang Wei; Sheng Zhang; Zhong-Yin Zhang; Yan Xu
Journal:  Am J Pathol       Date:  2011-05-17       Impact factor: 4.307

7.  Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.

Authors:  Minghai Shao; Stacy Hollar; Daphne Chambliss; Jordan Schmitt; Robert Emerson; Bhadrani Chelladurai; Susan Perkins; Mircea Ivan; Daniela Matei
Journal:  Mol Cancer Ther       Date:  2012-06-13       Impact factor: 6.261

8.  An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

9.  Lysophosphatidylglycerol inhibits formyl peptide receptorlike-1-stimulated chemotactic migration and IL-1beta production from human phagocytes.

Authors:  Jae Woong Shim; Seong Ho Jo; Sang Doo Kim; Ha Young Lee; Jeanho Yun; Yoe Sik Bae
Journal:  Exp Mol Med       Date:  2009-08-31       Impact factor: 8.718

10.  Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion.

Authors:  Dominique B Hoelzinger; Mitsutoshi Nakada; Tim Demuth; Tyler Rosensteel; Linsey B Reavie; Michael E Berens
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.